Angiopoietin 2 concentrations in infants developing bronchopulmonary dysplasia: Attenuation by dexamethasone

Journal of Perinatology

Volumn 28, Issue 2, 2008, Pages 149-155

  Aghai, Z H ^a   Faqiri, S ^a   Saslow, J G ^a   Nakhla, T ^a   Farhath, S ^a   Kumar, A ^a   Eydelman, R ^a   Strande, L ^a   Stahl, G ^a   Leone, P ^a   Bhandari, V ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; DEXAMETHASONE; OXYGEN;

ARTICLE; ASPIRATION; ASSISTED VENTILATION; BIRTH WEIGHT; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN MORBIDITY; OXYGEN THERAPY; PREMATURITY; PROTEIN DETERMINATION;

ANGIOPOIETIN-2; BODY FLUIDS; BRONCHOPULMONARY DYSPLASIA; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; TRACHEA;

EID: 38949137072     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211886     Document Type: Article

References (50)

1. Fanaroff AA, Hack M, Walsh MC. The NICHD neonatal research network: changes in practice and outcomes during the first 15 years. Semin Perinatol 2003; 27: 281-287.
2. Bhandari A, Bhandari V. Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front Biosci 2003; 8: E370-380.
3. Bhandari A, Bhandari V. Bronchopulmonary dysplasia: An update. Indian J Pediatr 2007; 74: 73-77.
4. Hamilton BE, Martin JA, Sutton PD. Births: Preliminary data for 2003. Natl Vital Stat Rep 2004; 53 1-17.
5. Akram Khan M, Kuzma-O'Reilly B, Brodsky NI, Bhandari V. Site-specific characteristics of infants developing bronchopulmonary dysplasia. J Perinatol 2006; 26: 428-435.
6. Bhandari V, Bizzarro WJ, Shelly A, Zhong X, Page GP, Zhang H et al Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 2006; 117: 1901-1906.
7. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
8. Gale-NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J et al Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3: 411-423.
9. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235-239.
10. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3: E46.
11. Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsigkos S, Dimopoulou I et al. Angiopoietin-2 is increased in severe sepsis: Correlation with lnflammatory mediators. Crit Care Med 2007; 35: 199-206.
12. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp GL et al Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 2006; 12: 1286-1293.
13. Fiedler U, Augustin HG. Angiopoietins: A link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552-558.
14. Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005; 314: 738-744.
15. Lemieux C, Maliba R, Favier J, Theoret JF, Merhi Y, Sirois MG. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 2005; 105: 1523-1530.
16. Gupta GK, Cole CH, Abbasi S, Demissie S, Njinimbam C, Nielsen HC et al. Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol 2000; 30: 275-281.
17. Munshi UK, Niu JO, siddiq MM, Parton IA. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasta. Pediatr Pulmonol 1997; 24: 331-336.
18. Tullus K, Noack GW, Burman LG, Nilsson R, Wretlind B, Brauner A. Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia. Eur J Pediatr 1996; 155: 112-116.
19. Kojima T, Sasai M, Kobayashi Y. Increased soluble ICAM-1 in tracheal aspirates of infants with bronchopulmonary dysplasia. Lancet 1993; 342: 1023-1024.
20. Kotecha S, Chan B, Azam N, Silverman M, Shaw RJ. Increase in interleukin-8 and soluble intercellular adhesion molecule-1 in bronchoalveolar lavage fluid from premature infants who develop chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1995; 72: F90-F96.
21. Kotecha S, Silverman M, Shaw RJ, Klein N. Soluble L-selectin concentration in bronchoalveolar lavage fluid obtained from infants who develop chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 1998; 78: F143-F147.
22. Jonsson B, Tullus K, Brauner A, Lu Y, Noack G. Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Child Fetal Neonatal Ed 1997; 77: F198-F201.
23. Kotecha S, Wilson I, Wangoo A, Silverman M, Shaw RJ. Increase in interleukin (IL)-1 beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res 1996; 40: 250-256.
24. Niu JO, Munshi UK, Siddiq MM, Parton IA. Early increase in endothelin-1 in tracheal aspirates of preterm infants: Correlation with brochopulmonary dysplasia. J Pediatr 1998; 132: 963-970.
25. Choi CW, Kim BI, Kim HS, Park JD, Choi JH. Son DW. Increase of interleukin-6 in tracheal aspirate at birth: A predictor of subsequent bronchopulmonary dysplasia in preterm infants. Acta Paediatr 2006; 95: 38-43.
26. Oei J, Lui K, Wang H, Henry R. Decreased interleukin-10 in tracheal aspirates from preterm infants developing chronic lung disease. Acta Paediatr 2002; 91: 1194-1199.
27. Takasaki J, Ogawa Y. Inteleukin 8 and granulocyte elastase alpha 1 proteinase inhibitor complex in the tracheobronchial aspirate of infants with chronic lung disease following inter-uterine infection. Acta Paediatr Jpn 1996; 38: 132-136.
28. Baier RJ, Loggins J, Kruger TE. Monocyte chemoattractant protein-1 and inteleukin-8 are increased in bronchopulmonary dysplasia: Relation to isolation of Ureaplasma urealyticum. J Investig Med 2001; 49 362-369.
29. Baier RJ, Majid A, Parupia H, Loggins J, Kruger TE. CC chemokine concentrations increase in respiratory distress syndrome and correlate with development of bronchopulmonary dysplasia. Pediatr Pulmonol 2004; 37: 137-148.
30. Kotecha S, Wangoo A, Silverman M, Shaw RJ. Increase in the concentration of transforming growth factor beta-1 in bronchoalveolar lavage fluid before development of chronic lung disease of prematurity. J Pediatr 1996; 128: 464-469.
31. Ambalavanan N, Novak ZE. Peptide growth factors in tracheal aspirates of mechanically ventilated preterm neonates. Pediatr Res 2003; 53 240-244.
32. Kazzi SN, Romero R, McLaughlin K, Ager J, Janisse J. Serial changes in levels of IL-6 and IL-1beta in premature infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol 2001; 31: 220-226.
33. Lassus P, Nupponen I, Kari A, Pohjavuori M, Andersson S. Early postnatal dexamethasone decreases hepatocyte growth factor in tracheal aspirate fluid from premature infants. Pediatrics 2002; 110: 768-771.
34. Danan C, Franco ML, Jarreau PH, Dassieu G, Chailley-Heu B, Bourbon J et al. High concentrations of keratinocyte growth fachor in airways of premature infants predicted absence of bronchopulmonary dysplasia. Am J Respir Crit Care Med 2002; 165: 1384-1397.
35. Rehan VK, Torday JS. Lower parathyroid hormone-related protein content of tracheal aspirates in very low birth weight infants who develop bronchopulmonary dysplasia. Pediatr Res 2006; 60: 216-220.
36. Lassus P, Ristimaki A, Ylikorkala O, Viinikka L, Anderson S. Vascular endothelial growth factor in human preterm lung. Am J Respir Crit Care Med 1999, 159: 1429-1433.
37. D'Angio CT, Basavegowda K, Avissar NE, Finkelstein JN, Sinkin RA. Comparison of tracheal aspirate and bronchoalveolar lavage specimens from premature infants. Biol Neonate 2002; 82: 145-149.
38. Nedrelow JH, Bhandari V. Interleukin (IL)-6 to vascular endothelial growth factor (VEGF) ratio predicts the development of Bronchopulmonary Dysplasia (BPD)/death in premature infants. Pediatr Res 2004; 55: 496A.
39. Watts CL, Bruce MC. Comparison of secretory component for immunoglobulin A with albumin as reference proteins in tracheal aspirate from preterm infants. J Pediatr 1995; 127: 113-122.
40. Cederqvist K, Sorsa T, Tervahartiala T, Maisi P, Reunanen K, Lassus P et al. Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics 2001; 108: 686-692.
41. Watts CL, Fanaroff AA, Bruce MC. Elevation of fibronectin levels in lung secretions of infants with respiratory distress syndrome and development of bronchopulmonary dysplasia. J Pediatr 1992; 120: 614-620.
42. Lassus P, Heikkila P, Andersson LC, von Boguslawski K, Andersson S. Lower concentration of pulmonary hepatocyte growth factor is associated with more severe lung disease in preterm infants. J Pediatr 2003; 143: 199-202.
43. Ekekezie II, Thibeault DW, Simon SD, Norberg M, Merrill JD, Ballard RA et al. Low levels of tissue inhibitors of metalloproteinases with a high matrix: Metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease. Pediatrics 2004, 113 1709-1714.
44. de Blic J, Midulla F, Barbato A, Clement A, Dab I, Eber E et al. Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society. Eur Respir J 2000; 15: 217-231.
45. Cayabyab RG, Jones CA, Kwong KY, Hendershott C, Lecart C, Minoo P et al. Interleukin-1beta in the bronchoalveolar lavage fluid of premature neonates: A marker for maternal diorioamnionitis and predictor of adverse neonatal outcome. J. Matern Fetal Neonatal Med 2003; 14: 205-211.
46. Mahieu LM, De Dooy JJ, Ieven MM, Bridts CH, Stevens WJ. Increased levels of tumor necrosis factor-alpha and decreased levels of interleukin 12 p 70 in tracheal aspirates, within 2 h after birth, are associated with mortality among ventilated-preterm infants. Pediatr Crit Care Med 2005; 6: 682-689.
47. Bhandari V, Elias JA. Cytokines in tolerance to hyperoxia-induced injury in the developing and adult lung. Free Radic Biol Med 2006; 41 4-18.
48. D'Angio CT, Maniscalco WM, Ryan RM, Avissar NE, Basavegowda K, Sinkin RA. Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: Effects of age and postnatal dexamethasone. Biol Neonate 1999; 76: 266-273.
49. Yoder Jr MC, Chua R, Tepper R. Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia. Am Rev Respir Dis 1991; 143: 1044-1048.
50. Wang JY, Yeh TF, Lin YJ, Chen WY, Lin CH. Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Pediatr Pulmonol 1997; 23: 193-197.